心脏瓣膜门诊随访对中度及无症状重度主动脉瓣狭窄患者结局的影响
该单中心观察性注册研究纳入2129例中度及无症状重度主动脉瓣狭窄患者,比较心脏瓣膜门诊(HVC)与标准诊疗(SOC)的结局。中位随访4.8±1.8年,HVC组全因死亡风险显著低于SOC组(HR=0.63,95%CI 0.40-0.98,P=0.038),心血管死亡亦降低(P=0.030),多变量分析显示HVC是全因死亡的独立预测因子(HR=0.54,95%CI 0.34-0.85,P=0.007)。
要点
- HVC随访与中度及无症状重度主动脉瓣狭窄患者全因死亡和心血管死亡降低相关。
- HVC组每年会诊次数、运动负荷试验、BNP检测和CT检查均更多(P<0.05)。
- HVC组从AVR指征到手术时间更短,NYHA心功能分级更轻(P<0.001和P=0.032)。
核心结论
- 对于中度及无症状重度主动脉瓣狭窄患者,HVC随访模式较SOC带来更高效的管理和结局获益。
研究设计与样本
- 单中心观察性注册研究,纳入2129例至少有一次心脏门诊就诊的中度及无症状重度主动脉瓣狭窄患者,按门诊策略分为HVC组(n=251)和SOC组(n=1878)。
主要发现
- 随访4.8±1.8年期间,822例(38.6%)死亡,307例(14.4%)因心力衰竭住院,596例(28%)接受主动脉瓣置换(AVR)。
- 倾向评分匹配后,HVC组每年会诊次数、运动负荷试验、BNP检测和CT检查均高于SOC组(P均<0.05)。
- HVC组从AVR指征到手术时间更短(P<0.001),NYHA心功能分级更轻(P=0.032)。
- 与SOC相比,HVC与全因死亡风险降低相关(HR=0.63,95%CI 0.40-0.98,P=0.038),心血管死亡亦降低(P=0.030)。
- 多变量分析中,HVC仍为全因死亡的独立预测因子(HR=0.54,95%CI 0.34-0.85,P=0.007)。
临床怎么用
- 对中度及无症状重度主动脉瓣狭窄患者,可考虑纳入HVC进行多学科团队管理以改善结局。
局限性
- 单中心观察性注册研究,存在选择偏倚可能;HVC组样本量较小(n=251)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart valve clinics (HVC) have been introduced to manage patients with valvular heart disease within a multidisciplinary team. OBJECTIVE: To determine the outcome benefit of HVC approach compared with standard of care (SOC) for patients with moderate and asymptomatic severe aortic stenosis (mAS and asAS). METHODS: Single-centre, observational registry of patients with mAS and asAS with at least one cardiac ambulatory consultation at our Cardiovascular Centre. Based on the outpatient strategy, patients were divided into HVC group, if receiving at least one visit at HVC, and SOC group, if followed by routine cardiac consultations. RESULTS: 2129 patients with mAS and asAS were divided into those followed in HVC (n=251) versus SOC group (n=1878). The mean age was 76.5±12.4 years; 919 (43.2%) had asAS. During a follow-up of 4.8±1.8 years, 822 patients (38.6%) died, 307 (14.4%) were hospitalised for heart failure and 596 (28%) underwent aortic valve replacement (AVR). After propensity score matching, the number of consultations per year, exercise stress tests, brain natriuretic peptide (BNP) determinations and CTs were higher in the HVC cohort (p<0.05 for all). A shorter time between indication of AVR and less advanced New York Heart Association class was reported in the HVC cohort (p<0.001 and p=0.032). Compared with SOC, the HVC approach was associated with reduced all-cause mortality (HR=0.63, 95% CI 0.40 to 0.98, p=0.038) and cardiovascular death (p=0.030). At multivariable analysis, the HVC remained an independent predictor of all-cause mortality (HR=0.54, 95% CI 0.34 to 0.85, p=0.007). CONCLUSIONS: In patients with mAS and asAS, the HVC approach was associated with more efficient management and outcome benefit compared with SOC.
引用
- Paolisso P, Beles M, Belmonte M, et al. Outcomes in patients with moderate and asymptomatic severe aortic stenosis followed up in heart valve clinics. Heart. 2023. PMID: 36598073. doi:10.1136/heartjnl-2022-321874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。